To Our Stockholders: As OXiGENE’s newly appointed President and Chief Executive Officer, it is a pleasure to have the opportunity to provide you with an update on OXiGENE’s progress this year and our outlook for the - Angiogenesis inhibitors - Document - PDFSEARCH.IO

First Page	Meta Content
	To Our Stockholders: As OXiGENE’s newly appointed President and Chief Executive Officer, it is a pleasure to have the opportunity to provide you with an update on OXiGENE’s progress this year and our outlook for the Add to Reading List Document Date: 2014-06-11 11:57:56 Open Document File Size: 100,13 KB Share Result on Facebook Company Gynecologic Oncology Group / PhD / / Country United Kingdom / / Currency USD / / Event FDA Phase / / Facility Baylor University / / MedicalCondition ovarian cancer / gastrointestinal neuroendocrine tumors / anaplastic thyroid cancer / advanced ovarian cancer / acute myeloid leukemia / / Organization European Union / Baylor University / Securities and Exchange Commission / National Health Service / / Person David (Dai) J. Chaplin / / Position President and Chief Executive Officer / Private / / Product Avastin / ZYBRESTAT / OXi4503 / AML / / Technology antibodies / drug development / / SocialTag Drug discovery Angiogenesis inhibitors Ovarian cancer Vascular-targeting agent Acute myeloid leukemia Cancer Clinical trial Bevacizumab Cyclacel Medicine

To Our Stockholders: As OXiGENE’s newly appointed President and Chief Executive Officer, it is a pleasure to have the opportunity to provide you with an update on OXiGENE’s progress this year and our outlook for the Add to Reading List